We are delighted to announce that the closing of Xeltis’ Series B financing generated a wave of interest in the media worldwide. Biocentury, Fierce Medical Devices, Biotech Finances and the Eindhovens Dagblad, the largest newspaper in the south of the Netherlands, are some of the media featuring the closing of our investment round. The latter wrote not only about the “financial injection for Xeltis”, as written in the Dutch original version, but also described our company’s first product, the pulmonary valve, and the development of Endogeneous Tissue Growth.
